- Home
- DWTX vs APRE Comparison
DWTX vs APRE Comparison
Compare DWTX & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DWTX
- APRE
- Stock Information
- Founded
- DWTX 2012
- APRE 2006
- Country
- DWTX United States
- APRE United States
- Employees
- DWTX N/A
- APRE N/A
- Industry
- DWTX
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DWTX
- APRE Health Care
- Exchange
- DWTX NYSE
- APRE Nasdaq
- Market Cap
- DWTX 9.2M
- APRE 10.0M
- IPO Year
- DWTX N/A
- APRE 2019
- Fundamental
- Price
- DWTX $4.95
- APRE $1.65
- Analyst Decision
- DWTX Strong Buy
- APRE Strong Buy
- Analyst Count
- DWTX 1
- APRE 2
- Target Price
- DWTX $10.00
- APRE $15.50
- AVG Volume (30 Days)
- DWTX 39.8K
- APRE 51.7K
- Earning Date
- DWTX 08-14-2025
- APRE 08-11-2025
- Dividend Yield
- DWTX N/A
- APRE N/A
- EPS Growth
- DWTX N/A
- APRE N/A
- EPS
- DWTX N/A
- APRE N/A
- Revenue
- DWTX N/A
- APRE $1,284,475.00
- Revenue This Year
- DWTX N/A
- APRE N/A
- Revenue Next Year
- DWTX N/A
- APRE N/A
- P/E Ratio
- DWTX N/A
- APRE N/A
- Revenue Growth
- DWTX N/A
- APRE 33.27
- 52 Week Low
- DWTX $1.62
- APRE $1.41
- 52 Week High
- DWTX $29.28
- APRE $5.01
- Technical
- Relative Strength Index (RSI)
- DWTX N/A
- APRE 47.84
- Support Level
- DWTX N/A
- APRE $1.48
- Resistance Level
- DWTX N/A
- APRE $1.81
- Average True Range (ATR)
- DWTX 0.00
- APRE 0.15
- MACD
- DWTX 0.00
- APRE -0.01
- Stochastic Oscillator
- DWTX 0.00
- APRE 45.45
About DWTX DOGWOOD THERAPEUTICS INC
Dogwood Therapeutics Inc, formerly Virios Therapeutics Inc, is a development-stage biotechnology company. It is focused on advancing novel antiviral therapies to treat diseases associated with a virus-triggered abnormal immune response, such as fibromyalgia (FM) and long COVID (LC). Its product candidates include IMC-1 and IMC-2. IMC-1 is intended to synergistically suppress herpesvirus activation and replication with a more specific activity against the Epstein-Barr virus (herpesvirus HHV-4, IMC-2 is a combination of valacyclovir and celecoxib.
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.